Keywords
Last Name

Vipul C. Chitalia, M.D., Ph.D.

TitleAssistant Professor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionNephrology
Phone(617) 414-1773
ORCID ORCID Icon0000-0002-6663-6058
Other Positions
TitleGraduate Faculty (Primary Mentor of Grad Students)
InstitutionBoston University School of Medicine, Division of Graduate Medical Sciences

TitleActive Staff Hospital Privileges
InstitutionBoston Medical Center
DepartmentMedicine

 Awards and Honors

Start-EndDescription
2016Boston University : Outstanding Mentor award for UROP mentoring
2015-2017Boston University School of Medicine: Evan’s Junior Faculty Merit Award
2007Boston University School of Medicine: Annual Evan’s Research Day award
2005Boston University School of Medicine: Annual Evan’s Research Day award
1998-1999International Society of Nephrology: International Society of Nephrology Fellowship award
1995University of Bombay: Gold medal Postdoctoral examination in Nephrology
1990-1992University of Bombay: Merit Scholarship, Government of India
1987University of Bombay: Charles Moorhead Prize
 Research Expertise & Professional Interests
Our laboratory focuses on the role of post-translational modifications of proteins, especially polyubiquitnation of the key mediators of vascular pathologies in diseases such as cancer and renal failure. While these diseases are discrete, several fundamental biological processes remain similar. Through a highly collaborative network, our laboratory harnesses the power of various cellular and molecular biological tools, relevant animal models (zebrafish and mice), computational methods and machine-learning techniques and strives to validate these findings and hypotheses in humanized models or human samples from large data bases, which highlights the translational nature of our approach.

A. Vascular diseases in kidney failure: Close to 20 million Americans or 10% of US population suffer from the chronic kidney disease (CKD). Among plethora of cardiovascular manifestations, CKD patients are particularly at high risk for both venous and arterial thrombosis, especially after vascular injury (endovascular injury such as angioplasty or stents; and surgical injury such as arteriovenous fistula creation) in CKD patients. This area of CKD management warrants urgent investigation due to lack of risk predictors and CKD-specific therapeutic targets.
Renal failure results in the retention of several chemical compounds, which unleash cellular toxicity, and hence called uremic solutes/toxins. While investigating the molecular pathogenesis of uremic toxicity, our laboratory was the first to demonstrate the prothrombotic propensity of indolic uremic solutes, which inhibits the ubiquitination of tissue factor, a bona fide member of the extrinsic coagulation pathway. Further investigation revealed Aryl Hydrocarbon Receptor (AHR) pathway as a critical mediator of tissue factor ubiquitination and thrombosis. Leveraging the ligand and the mediator, our lab aims to gain a deeper understanding into the mechanism of this unique uremic thrombosis axis (uremic solutes- AHR- TF- thrombosis) and to develop biomarkers and novel compounds to improve the management of the CKD patients with thrombosis after interventions in various vascular beds including coronary artery and arteriovenous fistula, etc.
Thrombosis being a dynamic and the multicomponent process, our laboratory has taken a holistic approach, under the co-directorship of Drs. Chitalia and Ravid, the Department of Medicine of BUSM and established a Thrombosis and Hemostasis ARC, which is a multidisciplinary platform of cell and molecular biologists, clinicians (cardiologists, vascular medicine, nephrologists and hematologists), computational biologists, biomedical engineers and statisticians and mathematicians to investigate various facets of thrombosis. http://www.bumc.bu.edu/evanscenteribr/the-arcs/the-arcs/

B. Angiogenesis: Angiogenesis, a process of generation of novel blood vessel is fundamental during the development and in various diseases such as cancer. Wnt signaling, a highly conserved oncogenic pathway is critical in angiogenesis. Beta catenin is the prime mediator of Wnt activation. Focusing on the ubiquitination and proteasomal degradation of beta catenin, our previous work had described Jade-1, as an E3 ligases of wild-type beta catenin. Our recent efforts have specifically focused on c-Cbl as an E3 ligase for the mutant beta catenin and for the transcriptionally active beta catenin in the nucleus. These two species of beta catenin, once considered resistant to degradation are effectively downregulated by c-Cbl. Thus, c-Cbl is a unique E3 ligase of tumorigenic beta catenin, which is involved in several cancers including colorectal cancer pathogenesis. Leveraging the cancer animal models and human cancer samples including machine learning based quantitative histology! techniques, our group investigates the colorectal cancer pathogenesis to gain deeper understanding of the role of E3 ligases of beta catenin E3 ligases in various cancers.

 Self-Described Keywords
  • Uremic Vascular Disease
  • Wnt Signaling
  • Chronic Kidney Disease
  • Thrombosis
  • E3 Ubiquitin Ligase
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Shashar M, Siwak J, Tapan U, Lee SY, Meyer RD, Parrack P, Tan J, Khatami F, Francis J, Zhao Q, Hartshorn K, Kolachalama VB, Rahimi N, Chitalia V. c-Cbl mediates the degradation of tumorigenic nuclear ß-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 2016 11 01; 7(44):71136-71150. PMID: 27661103.
    View in: PubMed
  2. Moshe Shashar, Jamaica Siwak, Umit Tapan, Shin Yin Lee, Rosana D. Meyer, Paige Parrack, Josenia Tan, Fatemeh Khatami, Jean Francis, Qing Zhao, Kevan Hartshorn, Vijaya B. Kolachalama, Nader Rahimi and Vipul Chitalia. c-Cbl mediates the degradation of tumorigenic nuclear ß-catenin contributing to the heterogeneity in Wnt activity in colorectal tumors. Oncotarget. 2016; (Epub).
    View in: External Website
  3. Arafa E, Bondzie PA, Rezazadeh K, Meyer RD, Hartsough E, Henderson JM, Schwartz JH, Chitalia V, Rahimi N. TMIGD1 is a novel adhesion molecule that protects epithelial cells from oxidative cell injury. Am J Pathol. 2015 Oct; 185(10):2757-67. PMID: 26342724.
    View in: PubMed
  4. Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H, Smith LE, Jiang Y, Costello CE, Rahimi N. Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis. 2015 Oct; 18(4):449-62. PMID: 26059764.
    View in: PubMed
  5. Shivanna S, Kolandaivelu K, Shashar M, Belghasim M, Al-Rabadi L, Balcells M, Zhang A, Weinberg J, Francis J, Pollastri MP, Edelman ER, Sherr DH, Chitalia VC. The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol. 2016 Jan; 27(1):189-201. PMID: 26019318.
    View in: PubMed
  6. Vipul Chitalia. Good-in-good-out: Diet modification in chronic kidney disease. Science Translational Medicine. 2015; 7(280):280.
    View in: External Website
  7. Shivanna S, Harrold I, Shashar M, Meyer R, Kiang C, Francis J, Zhao Q, Feng H, Edelman ER, Rahimi N, Chitalia VC. The c-Cbl ubiquitin ligase regulates nuclear ß-catenin and angiogenesis by its tyrosine phosphorylation mediated through the Wnt signaling pathway. J Biol Chem. 2015 May 15; 290(20):12537-46. PMID: 25784557.
    View in: PubMed
  8. Shashar M, Francis J, Chitalia V. Thrombosis in the uremic milieu--emerging role of "thrombolome". Semin Dial. 2015 Mar-Apr; 28(2):198-205. PMID: 24962903.
    View in: PubMed
  9. Voyvodic PL, Min D, Liu R, Williams E, Chitalia V, Dunn AK, Baker AB. Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow. J Biol Chem. 2014 Apr 4; 289(14):9547-59. PMID: 24554698.
    View in: PubMed
  10. Hartsough EJ, Meyer RD, Chitalia V, Jiang Y, Marquez VE, Zhdanova IV, Weinberg J, Costello CE, Rahimi N. Lysine methylation promotes VEGFR-2 activation and angiogenesis. Sci Signal. 2013 Dec 3; 6(304):ra104. PMID: 24300896.
    View in: PubMed
  11. Chitalia V, Shivanna S, Martorell J, Meyer R, Edelman E, Rahimi N. c-Cbl, a ubiquitin E3 ligase that targets active ß-catenin: a novel layer of Wnt signaling regulation. J Biol Chem. 2013 Aug 9; 288(32):23505-17. PMID: 23744067.
    View in: PubMed
  12. Franses JW, Drosu NC, Gibson WJ, Chitalia VC, Edelman ER. Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis. Int J Cancer. 2013 Sep 15; 133(6):1334-44. PMID: 23463345.
    View in: PubMed
  13. Chitalia VC, Shivanna S, Martorell J, Balcells M, Bosch I, Kolandaivelu K, Edelman ER. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation. 2013 Jan 22; 127(3):365-76. PMID: 23269489.
    View in: PubMed
  14. Foy RL, Chitalia VC, Panchenko MV, Zeng L, Lopez D, Lee JW, Rana SV, Boletta A, Qian F, Tsiokas L, Piontek KB, Germino GG, Zhou MI, Cohen HT. Polycystin-1 regulates the stability and ubiquitination of transcription factor Jade-1. Hum Mol Genet. 2012 Dec 15; 21(26):5456-71. PMID: 23001567.
    View in: PubMed
  15. Chitalia VC, Murikipudi S, Indolfi L, Rabadi L, Valdez R, Franses JW, Edelman ER. Matrix-embedded endothelial cells are protected from the uremic milieu. Nephrol Dial Transplant. 2011 Dec; 26(12):3858-65. PMID: 21795755.
    View in: PubMed
  16. Franses JW, Baker AB, Chitalia VC, Edelman ER. Stromal endothelial cells directly influence cancer progression. Sci Transl Med. 2011 Jan 19; 3(66):66ra5. PMID: 21248315.
    View in: PubMed
  17. Balcells M, Martorell J, Olivé C, Santacana M, Chitalia V, Cardoso AA, Edelman ER. Smooth muscle cells orchestrate the endothelial cell response to flow and injury. Circulation. 2010 May 25; 121(20):2192-9. PMID: 20458015.
    View in: PubMed
  18. Chitalia VC, Foy RL, Bachschmid MM, Zeng L, Panchenko MV, Zhou MI, Bharti A, Seldin DC, Lecker SH, Dominguez I, Cohen HT. Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol. 2008 Oct; 10(10):1208-16. PMID: 18806787.
    View in: PubMed
  19. Foy RL, Song IY, Chitalia VC, Cohen HT, Saksouk N, Cayrou C, Vaziri C, Côté J, Panchenko MV. Role of Jade-1 in the histone acetyltransferase (HAT) HBO1 complex. J Biol Chem. 2008 Oct 24; 283(43):28817-26. PMID: 18684714.
    View in: PubMed
  20. Zhou MI, Foy RL, Chitalia VC, Zhao J, Panchenko MV, Wang H, Cohen HT. Jade-1, a candidate renal tumor suppressor that promotes apoptosis. Proc Natl Acad Sci U S A. 2005 Aug 2; 102(31):11035-40. PMID: 16046545.
    View in: PubMed
  21. Chitalia VC, Almeida AF, Rai H, Bapat M, Chitalia KV, Acharya VN, Khanna R. Is peritoneal dialysis adequate for hypercatabolic acute renal failure in developing countries? Kidney Int. 2002 Feb; 61(2):747-57. PMID: 11849419.
    View in: PubMed
  22. Chitalia VC, Kothari J, Wells EJ, Livesey JH, Robson RA, Searle M, Lynn KL. Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio. Clin Nephrol. 2001 Jun; 55(6):436-47. PMID: 11434354.
    View in: PubMed
  23. Chitalia VC, Kolhe N, Kothari J, Almeida AF. Acute renal failure in a renal transplant donor due to primary antiphospholipid syndrome. Am J Nephrol. 2001 Jan-Feb; 21(1):55-7. PMID: 11275634.
    View in: PubMed
  24. Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int. 1999 Dec; 56(6):2236-42. PMID: 10594800.
    View in: PubMed
  25. Chitalia VC, Almeida AF, Krishnan M, Chauhan SK, Khetan PP. Minimal change nephrosis and antiphospholipid antibodies: coincidental or associated? Nephrol Dial Transplant. 1998 Dec; 13(12):3275-6. PMID: 9870515.
    View in: PubMed
  26. Almeida AF, Gunjotikar RV, Chitalia V. Dyslipidemia in chronic renal failure patients. J Postgrad Med. 1994 Apr-Jun; 40(2):52-4. PMID: 8737550.
    View in: PubMed
  27. Vipul C Chitalia. A Tug of War in the Periphery. Science Translational Medicine. 2(262):194.
    View in: External Website
  28. Vipul C Chitalia. Muscles Protect the Kidneys. Science Translational Medicine. 268(6):219.
    View in: External Website
  29. Vipul C Chitalia. AHR: A Temple of Tolerance to Toxemia. Science Translational Medicine. 6(250):142.
    View in: External Website
  30. Vipul C Chitalia. Inflammatory Web Catches Vessels. Science Translational Medicine. 6(232):67.
    View in: External Website
  31. Vipul C Chitalia. Keeping the Flow Going: FGFR1 Protects Vascular Patency by Inhibiting Occlusive Neointimal Hyperplasia. Science Translational Medicine. 6(258):178.
    View in: External Website
  32. Vipul C Chitalia. a-Ketoglutarate—A New Currency of Longevity. Science Translational Medicine. 6(244):117.
    View in: External Website
  33. Vipul C Chitalia. Angiotensin Blockade—A Double-Edged Sword in Renal Failure. Science Translational Medicine. 6(238):93.
    View in: External Website
Vipul's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department